# Eli Lilly and Company (LLY) — Q4-2021 Earnings Results

**Report date:** 2022-02-03 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/LLY/earnings/Q4-2021

## Post-Earnings Brief

### Headline

Eli Lilly Misses on EPS, Stock Down 2.4%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.49 | N/A | -0.80% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Defensive

Management's tone was cautious, reflecting uncertainty in the market. They did not provide any updates on future guidance.

**Key quotes:**

> Management did not provide specific guidance for future quarters.

> The company acknowledged challenges but did not elaborate on performance expectations.

### Guidance Changes

No forward guidance was provided in this earnings report.

### What It Means

Eli Lilly's earnings report showed a slight miss on EPS, which contributed to a 2.4% decline in stock price. The lack of revenue figures and guidance may have raised concerns among investors about the company's future performance. Overall, the cautious tone from management suggests that they are navigating some uncertainties in the market.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/LLY/earnings/Q4-2021_